File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2165/11596230-000000000-00000
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Drug-related problems in hospitalised children in the United Kingdom and Saudi Arabia
Title | Drug-related problems in hospitalised children in the United Kingdom and Saudi Arabia |
---|---|
Authors | |
Keywords | Pharmacy and pharmacology |
Issue Date | 2011 |
Publisher | Adis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/ |
Citation | The 11th Annual Meeting of the International Society of Pharmacovgilance (ISoP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 983, abstract no. PP166 How to Cite? |
Abstract | BACKGROUND: Drug-related problem (DRP) is ‘‘an event or circumstance involving drug therapy that actually or potentially interferes with the desired health outcome’’.[1] The extent and characteristics of DRPs in children in the UK and Saudi Arabia (KSA) is unknown. AIM: Our aim was to identify the incidence and characteristics of DRPs in children attending A&E/admitted to a hospital in the two countries. METHODS: A prospective cohort study in children aged 0–18 years admitted to the medical ward, paediatric intensive care unit (PICU), and neonatal intensive care unit (NICU) or attending A&E during a three month period in two hospitals were carried out. Data were collected on a form adapted from the Pharmaceutical Care Network in Europe (PCNE) DRP-Registration Form V5.01. Patients’ charts, medical records and laboratory data were reviewed daily to identify DRPs; their preventability and severity were assessed. RESULTS: 990 children [median 3 years, IQR; 10 months – 8 years, 58.6% male] were included. 388 patients suffered from 546 DRPs. Overall DRP incidence was 39.2% (95% CI, 36.1, 42.3) being higher in KSA than in the UK (44.8% vs 33.3%, p< 0.001). Incidence was found to be highest in PICU (59.7%; 95% CI, 47.0, 71.5). Dosing problems were the most frequently reported DRPs (n= 303, 55.5%), followed by drug choice problems (n = 91, 16.7%). 80.0% of DRP cases were preventable; 71.4% (n = 390) DRPs were assessed as minor and 27.8%(n = 152) as moderate. 295 (54.0%) were totally resolved, of which 220 (74.6%) were resolved by pharmacists. CONCLUSIONS: DRPs are a significant problem in the paediatric population in the UK and KSA, the majority of which are preventable. Increased focus on paediatric pharmacology and pharmacotherapy within paediatric medical and nursing education is an important step in improving prescribing practices. |
Description | Poster Presentations: no. PP166 This journal issue contain abstracts of the 11th ISoP Annual Meeting |
Persistent Identifier | http://hdl.handle.net/10722/165608 |
ISSN | 2023 Impact Factor: 4.0 2023 SCImago Journal Rankings: 1.204 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rashed, AN | en_US |
dc.contributor.author | Neubert, A | en_US |
dc.contributor.author | Tomlin, S | en_US |
dc.contributor.author | Jackman, J | en_US |
dc.contributor.author | Alhamdan, H | en_US |
dc.contributor.author | Shaikh, A | en_US |
dc.contributor.author | Attar, A | en_US |
dc.contributor.author | Aseeri, M | en_US |
dc.contributor.author | Wong, ICK | en_US |
dc.date.accessioned | 2012-09-20T08:21:12Z | - |
dc.date.available | 2012-09-20T08:21:12Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | The 11th Annual Meeting of the International Society of Pharmacovgilance (ISoP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 983, abstract no. PP166 | en_US |
dc.identifier.issn | 0114-5916 | - |
dc.identifier.uri | http://hdl.handle.net/10722/165608 | - |
dc.description | Poster Presentations: no. PP166 | - |
dc.description | This journal issue contain abstracts of the 11th ISoP Annual Meeting | - |
dc.description.abstract | BACKGROUND: Drug-related problem (DRP) is ‘‘an event or circumstance involving drug therapy that actually or potentially interferes with the desired health outcome’’.[1] The extent and characteristics of DRPs in children in the UK and Saudi Arabia (KSA) is unknown. AIM: Our aim was to identify the incidence and characteristics of DRPs in children attending A&E/admitted to a hospital in the two countries. METHODS: A prospective cohort study in children aged 0–18 years admitted to the medical ward, paediatric intensive care unit (PICU), and neonatal intensive care unit (NICU) or attending A&E during a three month period in two hospitals were carried out. Data were collected on a form adapted from the Pharmaceutical Care Network in Europe (PCNE) DRP-Registration Form V5.01. Patients’ charts, medical records and laboratory data were reviewed daily to identify DRPs; their preventability and severity were assessed. RESULTS: 990 children [median 3 years, IQR; 10 months – 8 years, 58.6% male] were included. 388 patients suffered from 546 DRPs. Overall DRP incidence was 39.2% (95% CI, 36.1, 42.3) being higher in KSA than in the UK (44.8% vs 33.3%, p< 0.001). Incidence was found to be highest in PICU (59.7%; 95% CI, 47.0, 71.5). Dosing problems were the most frequently reported DRPs (n= 303, 55.5%), followed by drug choice problems (n = 91, 16.7%). 80.0% of DRP cases were preventable; 71.4% (n = 390) DRPs were assessed as minor and 27.8%(n = 152) as moderate. 295 (54.0%) were totally resolved, of which 220 (74.6%) were resolved by pharmacists. CONCLUSIONS: DRPs are a significant problem in the paediatric population in the UK and KSA, the majority of which are preventable. Increased focus on paediatric pharmacology and pharmacotherapy within paediatric medical and nursing education is an important step in improving prescribing practices. | - |
dc.language | eng | en_US |
dc.publisher | Adis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/ | - |
dc.relation.ispartof | Drug Safety | en_US |
dc.subject | Pharmacy and pharmacology | - |
dc.title | Drug-related problems in hospitalised children in the United Kingdom and Saudi Arabia | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Wong, ICK: wongick@hku.hk | en_US |
dc.identifier.authority | Wong, ICK=rp01480 | en_US |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.2165/11596230-000000000-00000 | - |
dc.identifier.hkuros | 207303 | en_US |
dc.identifier.volume | 34 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.spage | 983, abstract no. PP166 | en_US |
dc.identifier.epage | 983, abstract no. PP166 | en_US |
dc.publisher.place | New Zealand | - |
dc.description.other | The 11th Annual Meeting of the International Society of Pharmacovgilance (ISOP 2011), Istanbul, Turkey, 26-28 October 2011. In Drug Safety, 2011, v. 34 n. 10, p. 983, abstract no. PP166 | - |
dc.identifier.issnl | 0114-5916 | - |